Izalontamab brengitecan

伦康依隆妥单抗

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameIzalontamab brengitecan
Drug Alias NameIza-brenBL-B01D1BMS-986507
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Ed-04 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonistsDNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsUrologic Neoplasms +[37] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[37] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSichuan Baili Pharmaceutical Co LtdSystImmune
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co Ltd +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursKidney NeoplasmsUrologic Neoplasms +[36] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A